Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$134.6K
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
0.9%
Total Assets
2026 Q1
Total Liabilities
Last 4 Quarters
N/A
Book Value
Last 4 Quarters
N/A
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
Last 4 Quarters
N/A

Stock Price

Loading...
Market Cap: $1.56 Million

About ACRO Biomedical Co Ltd

ACRO Biomedical Co Ltd (OTC: ACBM) is a development-stage biomedical company pursuing the development and commercialization of cordyceps-infused animal feed products, specifically a cordyceps-infused chicken feed. The company has not demonstrated an ability to generate gross profit sufficient to sustain operations, as disclosed in its 10-K filed February 11, 2026. Revenue, if any, is expected to come from transactional product sales to chicken farmers and animal feed distributors. Prior end-user markets were concentrated in China and Hong Kong, per the same filing. The common stock trades on the OTC Markets Expert Market, where market makers cannot quote prices, and the most recent reported trade was $0.0007 as of June 30, 2025. The company requires significant external funding to develop and implement its business plan and has not yet secured distribution agreements or regulatory approvals necessary to market its proposed products.

Revenue model
Transactional product sales of cordyceps-infused chicken feed to chicken farmers and animal feed distributors, as described in the 10-K filed 2026-02-11. No revenue model is currently operational; the company is in a development stage.
Products and services
Cordyceps-infused chicken feed (proposed, not yet commercially launched as of the 10-K filed 2026-02-11).
Customers and end markets
Chicken farmers and animal feed distributors as direct customers; prior end-user markets concentrated in China and Hong Kong, per 10-K filed 2026-02-11.
Value-chain role
Product developer and prospective manufacturer of specialty animal feed ingredients; no distribution agreements in place as of 10-K filed 2026-02-11.
Geographic exposure
Prior end-user sales in China and Hong Kong; prospective U.S. market development noted as uncertain in 10-K filed 2026-02-11.

Source: SEC 10-K, filed 2026-02-11

Industry: Services-Amusement & Recreation Services Peers: Adapthealth Corp Fuse Medical Inc Cosmos Health Inc Great Elm Group Inc McKesson Corp PATTERSON COMPANIES, INC. Accendra Health Inc PetIQ, Inc.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support